Kinnate Biopharma (KNTE) News Today → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free KNTE Stock Alerts $2.66 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKinnate Biopharma Inc. (NASDAQ:KNTE) Short Interest Down 43.6% in Marchmarketbeat.com - March 28 at 10:30 AMCitigroup Inc. Increases Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)marketbeat.com - March 22 at 4:34 AMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMKinnate Biopharma (KNTE) to Release Quarterly Earnings on Wednesdaymarketbeat.com - March 12 at 7:35 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Given Consensus Recommendation of "Hold" by Brokeragesmarketbeat.com - March 7 at 5:47 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Stake Increased by Citigroup Inc.marketbeat.com - March 4 at 4:34 AMKinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratoriesmsn.com - March 1 at 9:12 PMKinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick Factsmarkets.businessinsider.com - March 1 at 2:49 PMKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratoriesprnewswire.com - March 1 at 8:35 AMKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratoriesglobenewswire.com - March 1 at 8:30 AMAcadian Asset Management LLC Raises Holdings in Kinnate Biopharma Inc. (NASDAQ:KNTE)marketbeat.com - February 29 at 5:45 AMStifel Nicolaus Boosts Kinnate Biopharma (NASDAQ:KNTE) Price Target to $2.59marketbeat.com - February 26 at 10:18 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMKinnate Biopharma just downgraded at William Blair, here's whyrealmoney.thestreet.com - February 17 at 3:06 PMPrivate equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as wellfinance.yahoo.com - February 17 at 10:04 AMALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.prnewswire.com - February 16 at 5:57 PMShareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMAprnewswire.com - February 16 at 2:25 PMKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholdersbusinesswire.com - February 16 at 10:07 AMKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholdersbusinesswire.com - February 16 at 9:09 AMKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Sharefinance.yahoo.com - February 16 at 8:52 AMKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Shareglobenewswire.com - February 16 at 8:00 AMmarketbeat.com - February 16 at 7:59 AMShort Interest in Kinnate Biopharma Inc. (NASDAQ:KNTE) Increases By 5.8%marketbeat.com - February 16 at 7:24 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Receives Average Recommendation of "Hold" from Brokeragesmarketbeat.com - February 11 at 3:16 AMLeerink Partnrs Weighs in on Kinnate Biopharma Inc.'s Q3 2024 Earnings (NASDAQ:KNTE)marketbeat.com - February 8 at 7:46 AMLeerink Partnrs Comments on Kinnate Biopharma Inc.'s Q1 2024 Earnings (NASDAQ:KNTE)marketbeat.com - February 7 at 8:06 AMAnalysts Issue Forecasts for Kinnate Biopharma Inc.'s Q2 2024 Earnings (NASDAQ:KNTE)marketbeat.com - January 19 at 8:15 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Forecasted to Earn Q1 2024 Earnings of ($0.41) Per Sharemarketbeat.com - January 18 at 7:31 AMWedbush Reiterates "Neutral" Rating for Kinnate Biopharma (NASDAQ:KNTE)marketbeat.com - January 17 at 8:46 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Sees Large Growth in Short Interestmarketbeat.com - January 14 at 8:18 PMKinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)seekingalpha.com - December 12 at 7:21 AMKinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investorsfinance.yahoo.com - November 24 at 1:58 PMWhy is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?msn.com - November 15 at 2:53 PMOrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma Incfinance.yahoo.com - November 15 at 9:52 AMKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 9 at 5:32 PMInstrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)theglobeandmail.com - October 4 at 8:48 AMKinnate Biopharma (KNTE) Falls 40% in a Month: Here's Whyfinance.yahoo.com - October 3 at 2:15 PMJefferies Maintains Kinnate Biopharma (KNTE) Buy Recommendationmsn.com - September 20 at 6:25 PMBay Area biotech company Kinnate to lay off 70% of workforcemsn.com - September 19 at 7:59 PMWedbush Downgrades Kinnate Biopharma (KNTE)msn.com - September 19 at 7:59 PMWhy Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?msn.com - September 19 at 2:58 PMPiper Sandler Downgrades Kinnate Biopharma (KNTE)msn.com - September 19 at 2:58 PMAnalysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuringmarkets.businessinsider.com - September 19 at 2:58 PMKinnate slashes workforce by 70%, shelves three drug programsmsn.com - September 18 at 11:38 PMKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuringfinance.yahoo.com - September 18 at 6:38 PMmarketbeat.com - September 18 at 4:07 PMKinnate Biopharma (KNTE) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 15 at 7:43 AMKinnate Biopharma Inc. Forecasted to Earn Q3 2023 Earnings of ($0.77) Per Share (NASDAQ:KNTE)marketbeat.com - August 14 at 2:16 AMFY2023 EPS Estimates for Kinnate Biopharma Inc. Boosted by Analyst (NASDAQ:KNTE)marketbeat.com - August 11 at 10:00 AMKinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - August 8 at 6:09 PM Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… KNTE Media Mentions By Week KNTE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNTE News Sentiment▼1.510.61▲Average Medical News Sentiment KNTE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNTE Articles This Week▼51▲KNTE Articles Average Week Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Immunic News Seres Therapeutics News Clearside Biomedical News Citius Pharmaceuticals News BeyondSpring News Cartesian Therapeutics News Adagene News Acrivon Therapeutics News Anixa Biosciences News Oramed Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNTE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.